ANVISA approves new Covid-19 vaccine

ANVISA has approved the registration of the Covid-19 vaccine (recombinant) from Zalika Farmacêutica Ltda.

A monovalent immunizer with recombinant protein S antigen and saponin adjuvant, increasing antibody production. Read more here

ELS helps from drug development to registration in Brazil, Latin America and Europe.

Please do not hesitate to contact your local ELS consultant or via email

Contact us

We will contact you as soon as possible.